Immune begins Phase I trial of G100 to treat metastatic sarcoma

Immune Design, a US-based clinical-stage immunotherapy firm, has initiated an investigator-sponsored Phase I clinical trial of its investigational immuno-oncology agent, G100, in combination with radiation therapy in patients with metastatic sarcoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news